Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 5/20 | 0.49 |
| ▸ | BCR | P11274 | 4/20 | 0.49 |
| ▸ | KDR | P35968 | 5/20 | 0.49 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.46 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.44 |
| ▸ | CFTR | P13569 | 1/20 | 0.44 |
| ▸ | ACHE | P22303 | 2/20 | 0.44 |
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.43 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.42 |
| ▸ | AURKA | O14965 | 3/20 | 0.41 |
| ▸ | FLT3 | P36888 | 3/20 | 0.41 |
| ▸ | CDK4 | P11802 | 1/20 | 0.41 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.41 |
| ▸ | CCND1 | P24385 | 1/20 | 0.41 |
| ▸ | CDK2 | P24941 | 1/20 | 0.41 |
| ▸ | CCND3 | P30281 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14090411 | 0.94 | EPHX2 (0.46) | ABL1BCRKDRSLC2A1AURKB | |
| SCHEMBL14090409 | 0.89 | CDK4 (0.42) | ABL1BCRSLC2A1HTR2AKCNH2 | |
| SCHEMBL12834010 | 0.88 | CHEK2 (0.47) | ABL1BCRKDRSLC2A1ACHE | |
| SCHEMBL12834188 | 0.87 | CDK4 (0.52) | KDRCDK4CCNA2CCND1CDK2 | |
| SCHEMBL14090412 | 0.87 | ABL1 (0.46) | ABL1BCRKDRACHEMCHR1 | |
| SCHEMBL12834486 | 0.86 | HPSE (0.48) | ABL1 | |
| SCHEMBL12833903 | 0.86 | CDK4 (0.47) | KDRCDK4CCNA2CCND1CDK2 | |
| SCHEMBL14090410 | 0.86 | KDR (0.47) | ABL1BCRKDR | |
| SCHEMBL14090414 | 0.86 | MCHR1 (0.51) | ABL1BCRKDRACHEMCHR1 | |
| SCHEMBL14090415 | 0.85 | MCHR1 (0.51) | ABL1ACHEMCHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8629147-B2 | Heterocyclic compounds useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders | CHEMBRIDGE CORPORATION (US) | 2014-01-14 | — | — | US | disclosed |
| US-8629147-B2 | Heterocyclic compounds useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders | CHEMBRIDGE CORPORATION (US) | 2014-01-14 | — | — | US | disclosed |
| US-20080207635-A1 | Heterocyclic compounds useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders | CHEMBRIDGE CORPORATION | 2008-08-28 | — | — | US | disclosed |
| US-20080207635-A1 | Heterocyclic compounds useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders | CHEMBRIDGE CORPORATION | 2008-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207635-A1 | Heterocyclic compounds useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders | LCK, MALT1, MYD88 | ABL1 37/4885BCR 150/4885KDR 1194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.